Kisspeptin
KISS1 Peptide / Metastin
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Kisspeptin is the master regulator of the hypothalamic-pituitary-gonadal axis and has genuine human clinical-research use, chiefly from the Imperial College London group led by Waljit Dhillo: Phase 2 randomized work using kisspeptin-54 as a safer trigger for oocyte maturation in IVF while nearly eliminating ovarian hyperstimulation syndrome risk, and randomized crossover trials showing kisspeptin modulates sexual brain processing and arousal in men and women with hypoactive sexual desire disorder. It remains investigational with no approved product, and the reproductive/IVF and sexual-desire indications are supported by preliminary and early-phase human data rather than confirmatory multi-RCT evidence, which places it honestly at grade 2.
- FDA
- No FDA-approved kisspeptin product; investigational only, tested in early-phase and Phase 2 academic trials (Imperial College London) for IVF oocyte-maturation triggering and hypoactive sexual desire disorder
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Investigational, no approved product; early-phase human safety data only, long-term and repeat-dose effects on the reproductive axis not established
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Kisspeptin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
The master regulator of the hypothalamic-pituitary-gonadal axis, named after Hershey's Kisses (it was discovered in Hershey, PA). Active Phase 2 trials are exploring it for male and female hypogonadism and sexual dysfunction.
The master switch for puberty and reproductive hormones. Named after Hershey Kisses.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Kisspeptin sits at the very top of the reproductive system, the master switch that starts the whole hormonal cascade. Kisspeptin neurons in the hypothalamus tell the GnRH neurons to fire, which triggers the pituitary to release LH and FSH, which in turn drive the gonads to make testosterone or estrogen. It is so fundamental that without it puberty never begins. Beyond hormones, kisspeptin also acts in the brain’s emotional and limbic regions to enhance how the brain processes sexual cues and to reduce sexual aversion, so it influences both the hormonal root of desire and the mind’s response to it.
Kisspeptin is a family of neuropeptides (including kisspeptin-54, -13 and -10) produced from the KISS1 gene, acting on the kisspeptin receptor. It is the upstream controller of the hypothalamic-pituitary-gonadal axis, the hormonal chain that governs reproduction. Its discovery rewrote the understanding of how puberty and fertility are switched on, and mutations that disable its receptor cause a failure of puberty, underlining how central it is.
- Type
- Reproductive-axis neuropeptide
- Gene
- KISS1
- Controls
- HPG axis (LH/FSH)
- Plus
- Sexual brain processing
- Stage
- Investigational (Phase I/II)
- Approved
- No
Real Science, Still Investigational
Kisspeptin is a refreshing case in this library, because unlike most sexual and reproductive peptides sold gray-market, it is backed by genuinely rigorous and promising human science. A serious academic program at Imperial College London has run multiple randomized, brain-imaging-controlled trials showing that kisspeptin enhances both the hormonal and the brain-level components of sexual desire, with an exceptionally clean safety profile, and it has a real fertility advantage, triggering egg maturation in IVF with far less risk of the dangerous ovarian overstimulation that standard methods can cause. That is exactly the kind of evidence worth taking seriously. The honest caveat is that it is still investigational: the sexual-function data is early-phase and smaller-scale, it is not approved for anything, and the gray-market kisspeptin sold for libido runs ahead of the still-maturing evidence. Real promise, on a solid footing, not yet proven.
Safety in detail
Human exposure to date comes largely from short single-dose or crossover research protocols in academic trials; kisspeptin has no FDA-approved formulation, and any product sold as a 'research peptide' is unapproved and not manufactured to clinical standards.
- Its side-effect profile is exceptionally clean, a notable strength, reflecting that it works through the body’s own natural reproductive pathway.
- In fertility care it offers a real safety advantage by reducing the risk of dangerous ovarian overstimulation compared with standard IVF triggers.
- It is investigational and not approved for any indication, so its longer-term profile is still being characterized.
- Because it raises testosterone through the reproductive axis, male athletes should be cautious about anti-doping implications and check the current code.
- Gray-market kisspeptin sold for libido carries the usual identity and purity risks and is not the same as the studied clinical product.
Children and teenagers
Kisspeptin is central to puberty and is studied within pediatric endocrinology for conditions like delayed puberty, strictly under specialist care. That is entirely separate from gray-market libido or sexual use, which has no place in minors. Any pediatric involvement belongs only within specialist endocrine medicine, never self-sourced.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Kisspeptin’s most important value is in legitimate development: the academic and clinical program advancing it toward potential approval for low sexual desire and for fertility uses. Around that sits the familiar gray market, vendors selling kisspeptin-10 as a libido supplement, and fertility clinics using it in research and IVF settings. Unusually for this library, the serious money and effort are on the rigorous-science side, with the gray-market libido market running ahead of where the approved evidence actually is.
How we got here
The name traces to 1996, when a Penn State College of Medicine team in Hershey, Pennsylvania identified a melanoma metastasis-suppressor gene and named it KiSS-1, a nod to the town's Hershey's Kisses. In 2001 the encoded 54-residue peptide was isolated as the endogenous ligand of the orphan receptor GPR54 and named metastin, before the broader family took the name kisspeptins, with fragments designated by residue count (KP-54, KP-14, KP-13, KP-10). Its role shifted from cancer biology to reproduction once GPR54 mutations were linked to hypogonadism, and the clinical research center of gravity moved to the Imperial College London group under Waljit Dhillo, which advanced kisspeptin-54 into human trials for IVF triggering and sexual-desire disorders. Research-chemical vendors now sell KP-54 and KP-10 as unapproved 'research' peptides, distinct from the investigational clinical-trial material.
Kisspeptin emerged from an unexpected place, a gene first linked to cancer-metastasis suppression, before researchers discovered in the early 2000s that its receptor is the master controller of reproduction, with receptor mutations causing failure of puberty. Waljit Dhillo’s group at Imperial College London then drove the human work: showing in 2005 that kisspeptin stimulates the reproductive axis, in 2017 that it modulates sexual brain processing, and in 2023 that it improves measures of sexual desire in men with HSDD. In parallel, it advanced as a safer trigger in IVF. Gray-market kisspeptin-10 for libido followed, running ahead of the still-developing approved evidence.
- Early 2000sThe kisspeptin receptor is identified as the master regulator of reproduction; mutations cause failed puberty.
- 2005Kisspeptin shown to stimulate the human reproductive axis.
- 2017Demonstrated to modulate sexual and emotional brain processing in humans.
- 2010sDeveloped as a safer ovulation trigger for IVF, reducing overstimulation risk.
- 2023A randomized trial shows benefit for men with low sexual desire, a potential first treatment.
The numbers behind the grade
- Type
- Reproductive neuropeptide (KISS1)
- Role
- HPG-axis master switch
- Sexual data
- Phase I/II, promising
- Fertility
- IVF-safety advantage
- Approved
- No
- Safety
- Exceptionally clean
The people taking it
The scientifically respected master switch of reproduction, with a genuinely promising and unusually rigorous research story in both fertility and low sexual desire, increasingly known in the sexual-health space.
Kisspeptin’s relevant populations are people with low sexual desire, both men and women, where the research is most promising, and fertility patients, including those undergoing IVF or with hypothalamic causes of infertility. Its gray-market users are the broader libido and sexual-health crowd, and some hormone-optimization users drawn by its testosterone-raising effect. The clinical interest is genuinely evidence-led, which sets its user story apart from most peptides here.
Studied for fertility (safer IVF triggering, hypothalamic infertility) and for low sexual desire in men and women, with promising early trials, and used gray-market for libido. Investigational and not yet approved.
Set against the alternatives
Against PT-141, the only approved sexual-desire peptide, kisspeptin is the investigational but mechanistically broader option: PT-141 acts on demand through melanocortin receptors and has FDA approval for women, while kisspeptin works through the reproductive axis and the limbic brain, has an exceptionally clean side-effect profile, and adds fertility applications PT-141 cannot touch, making them potentially complementary. Against PDE5 inhibitors like Viagra, which act on blood flow and erection, kisspeptin targets desire and the hormonal root rather than the plumbing. And in IVF, against the standard hCG trigger, kisspeptin offers a safer path with less overstimulation risk. Its strength is a uniquely broad, well-grounded mechanism; its limitation is that the sexual-function evidence is still early.
What we do not know
- Whether the promising early sexual-function results hold up in larger Phase III trials.
- Whether and when kisspeptin becomes an approved drug for low desire or for fertility.
- Which form and dose, such as kisspeptin-10 versus kisspeptin-54, work best.
- How durable and broadly applicable its sexual-function benefits prove to be.
What could change
Low-desire treatmentLarger trials could make kisspeptin the first real drug for male low desire, where nothing is approved.Fertility applicationsSafer IVF triggering and other reproductive uses continue to develop.Brain and behaviorFurther work on its limbic, desire-enhancing effects.Toward approvalThe key question is whether the rigorous early data carries into approval.
Legal status
Kisspeptin is investigational and not FDA-approved for any indication. It is used in clinical research for fertility and for low sexual desire, and in some fertility settings for safer IVF triggering. Gray-market kisspeptin-10 is sold as a libido supplement or research peptide, which is not an approved use. Its legitimate applications are currently within research and specialist care.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
There is no approved kisspeptin product to buy; gray-market kisspeptin-10 sold for libido is not an approved use and is not the studied clinical material. For low sexual desire, approved options like PT-141, along with PDE5 inhibitors and counseling, are the established routes, while fertility uses belong with specialists. Anyone using gray-market product should insist on third-party testing.
Gray-market kisspeptin-10 vials are relatively inexpensive. The research and fertility uses occur in clinical settings rather than through retail purchase. As with any gray-market peptide, low cost comes with no assurance of identity, dose or purity.
Legitimate kisspeptin comes through regulated research and clinical supply. Gray-market kisspeptin-10 comes from Chinese research synthesis with no quality assurance, where a certificate of analysis is the only check.
Research and clinicalThe trial program and fertility-clinic use draw on regulated, characterized material.China and research vendorsSupply gray-market kisspeptin-10 as research-use-only material for libido use.Fertility-medicine channelAcademic fertility centers use kisspeptin in IVF and reproductive research.
At a glance
- Role
- Master HPG-axis regulator
- Named for
- Hershey, Pennsylvania
- Stage
- Active Phase 2
- Use
- Hypogonadism, fertility
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Kisspeptin.
Nothing outstanding on this one.
Sources
Kisspeptin-54 triggers oocyte maturation in IVF with mature eggs, fertilization and pregnancy, in women at high OHSS risk (Phase 2, Dhillo group)
Abbara et al., Journal of Clinical Endocrinology & Metabolism (JCEM), Oxford Academic
A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of OHSS: Phase 2 randomized controlled trial
Kisspeptin-54 triggers egg maturation in women undergoing IVF (foundational clinical study)
Review of use of kisspeptin to trigger oocyte maturation during IVF treatment
Kisspeptin boosts sexual brain processing and penile tumescence in men with HSDD: randomized clinical trial
Kisspeptin administration modulates sexual and attraction brain processing in women with HSDD: randomized clinical trial
Imperial College institutional summary: kisspeptin injection could treat low sex drive in women and men; trials at Imperial, NIHR/MRC funded
KISS1 discovered 1996 as a melanoma metastasis-suppressor gene at Penn State College of Medicine in Hershey PA; named after Hershey's Kisses; kisspeptin-54 originally called metastin; receptor GPR54/KISS1R; no FDA-approved kisspeptin drug
KISS1 metastasis suppressor gene entry, molecular identity of KISS1 and its peptide products
Metastasis-suppressor gene KiSS-1 encodes the peptide ligand of a G-protein-coupled receptor (metastin/GPR54)
Kisspeptins as a multifunctional peptide system in reproduction, cancer and the cardiovascular system (review of biology and nomenclature)
The studies that matter
Dhillo et al2005
Showed kisspeptin stimulates the human reproductive axis, raising LH, FSH and testosterone, establishing its hormonal effect in people.
Comninos et al, J Clin Invest2017
Demonstrated that kisspeptin modulates sexual and emotional brain processing in humans, enhancing limbic responses to sexual stimuli, a brain effect beyond hormones.
Mills/Ertl et al, men with HSDD2023
A randomized trial in men with low sexual desire found kisspeptin substantially increased sexual brain activity, penile response and behavioral measures of desire versus placebo, the first evidence for a potential drug for male low desire.
Women’s sexual-function studies2010s-2020s
Kisspeptin enhanced genital arousal and sexual brain processing in women and correlated with reduced sexual distress.
IVF trigger studies2010s
Kisspeptin triggered egg maturation in IVF with much lower risk of ovarian hyperstimulation syndrome, a genuine fertility-safety advance.